Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...